(Q37661556)

21 August 2017

title

Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes (English)

1 reference

21 August 2017

0 references

0 references

Richard Scranton

1

1 reference

21 August 2017

Anthony Cincotta

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

11

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

269-279

1 reference

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

The involvement of dopamine in the modulation of sleep and waking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Fate and disposition of bromocriptine in animals and man. I: structure elucidation of the metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Bromocriptine: a novel approach to the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903501544

10.1517/14656560903501544

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference